drugset / Trial / NCT03946202

KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

NCT03946202 ↗

Phase 2 Active not recruiting 184 enrolled Institute of Cancer Research, United Kingdom Kortuc, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a study aimed at testing a commonly available and inexpensive chemical (hydrogen peroxide) for efficacy in sensitising large cancerous lumps in the breast to a standard course of radiotherapy in patients with locally advanced or recurrent breast cancer. Laboratory research and initial clinical trials in Japan suggest that 4 to 6 injections of a radiation sensitiser ('KORTUC') based on very dilute (0.5%) hydrogen peroxide injected into cancers under local anaesthetic twice a week during radiotherapy greatly increases the effectiveness of standard doses of radiotherapy alone. The side effects are limited to mild/moderate discomfort at the injection site for up to 24 hours reported by Japanese breast cancer patients in whom this treatment has been tested. Complete tumour shrinkage in 70/71 (98%) primary breast cancers up to 5 cm diameter have been reported by Japanese collaborators.

Timeline

Start
2020-06-16
Primary completion
2028-08-31
Completion
2028-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrogen Peroxide Small molecule 0.5 % Other

Indications